Itolizumab

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

Product Specifications

CAS Number

[1116433-11-4]

Product Name Alternative

Anti-Human CD6 Recombinant Antibody

UNSPSC

12352203

Target

CD6

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/itolizumab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Itolizumab]

Molecular Weight

(146.66 kDa)

References & Citations

[1]Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17 (1) :34. |[2]Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20 (9) :1025-1031. |[3]Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62 (4) :418-421. |[4]Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. |[5]Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13 (1) :3688. |[6]Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12 (7) :e0180088. |[7]Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1) : 5603.